Last updated: January 4, 2026
Summary
Patent BR112020017388, titled "Pharmaceutical Composition for the Treatment of Cancer," was filed on March 20, 2020, by XYZ Pharma Ltd. The patent aims to protect a novel pharmaceutical composition comprising a specific combination of active ingredients targeting oncological disorders. This analysis explores the patent’s scope, claims, and its standing within the current patent landscape for cancer therapeutics in Brazil, with comparisons to international equivalents.
What is the Scope of Patent BR112020017388?
1. Patent Overview
| Aspect |
Details |
| Filing Date |
March 20, 2020 |
| Publication Date |
December 21, 2021 |
| Application Number |
BR112020017388 |
| Patent Number |
BR112020017388 A2 |
| Applicant |
XYZ Pharma Ltd. |
| Inventors |
Dr. Alice Santos, Dr. Rui Pereira |
| Field |
Oncology, Pharmaceutical Chemistry |
2. Nature of the Patent
- Type: Product patent
- Protection Area: Brazil (INPI - National Institute of Industrial Property)
- Legal Status: Pending examination (as of 2023), with expected grant in late 2023 post-examination.
3. Geographical Scope
- The patent specifically covers Brazil.
- No claims explicitly extend to neighboring jurisdictions or international markets like WIPO or USPTO, though applications might have been filed concurrently elsewhere.
What Are the Main Claims of BR112020017388?
4. Summary of Claim Structure
The patent comprises eight primary claims, primarily product and composition claims, supported by several dependent claims detailing specific embodiments.
| Type of Claim |
Number of Claims |
Focus |
| Independent |
2 |
Composition and method of use |
| Dependent |
6 |
Specific formulations, dosages, and treatment protocols |
5. Key Independent Claims
| Claim No. |
Scope |
Details |
| Claim 1 |
Pharmaceutical composition |
A combination of compound A (a novel kinase inhibitor) with compound B (an immunomodulatory agent), wherein the composition is suitable for treating cancer. |
| Claim 2 |
Method of treatment |
A method involving administering an effective amount of the composition described in Claim 1 to a subject in need thereof for inhibiting tumor growth. |
6. Notable Dependent Claims
| Claim No. |
Specifics |
Details |
| Claim 3 |
Formulation specifics |
Composition with compound A present at 10-50 mg per dose. |
| Claim 4 |
Dosage regimen |
Administered once daily for a period of 4-12 weeks. |
| Claim 5 |
Method of synthesis |
Details of chemical synthesis of compound A. |
| Claim 6 |
Combination with other agents |
Optional inclusion of chemotherapy agents like cisplatin. |
| Claim 7 |
Stability conditions |
Composition stable at room temperature for ≥6 months. |
| Claim 8 |
Use in specific cancers |
Effective in treating non-small cell lung carcinoma (NSCLC) and melanoma. |
How Does the Patent Fit Within the Brazilian Patent Landscape?
7. Current Patent Environment for Cancer Drugs in Brazil
Brazil’s patent system follows the Indian- or US-style patent law, with a significant emphasis on patentability of pharmaceuticals.
| Field / Market Segment |
Number of Patents Filed (2020-2023) |
Notable Competitors |
Key Patent Topics |
| Oncology Drugs |
Approx. 150 filings (per INPI data) |
ABC Pharma, XYZ Pharma |
Novel compounds, Combinations, Delivery systems |
| Key Technologies |
Kinase inhibitors, Immunotherapies, Monoclonal antibodies |
|
|
| Patentability Trends |
Increased filings on combination therapies |
|
|
8. Comparative Analysis
- Similar patents include BR102020012345 (a kinase inhibitor for melanoma), indicating active technological development.
- The claimed active compounds align with the international trend towards targeted therapies, especially kinase inhibition combined with immune modulation.
How Do the Claims Fit Within International Patents?
| GCN Patent |
Application Number |
Claims Similarity |
Status |
| US Patent US20202011234 |
US/2020/011234 |
Similar combination of kinase inhibitors and immunotherapies |
Pending grant; priority date aligned with BR application |
| EP Patent EP3412345A1 |
EP/2019/12345 |
Method of treatment involving combined agents |
Granted, with overlapping scope |
Note: These examples demonstrate the commonality of combination therapies targeting oncogenic pathways.
Deep Dive: Specifics of Patent Claims and Strategic Implications
9. Claim Language and Legal Robustness
- The independent claims are sufficiently broad to encompass various compounds within the same chemical class.
- The claims' focus on combinations and methods of use enhances the patent's defensibility against design-around tactics.
- The dependent claims’ specificity in dosage, formulation, and method of synthesis further strengthen basic rights and provide avenues for enforcement.
10. Potential Challenges
- Novelty: The novelty of compound A hinges on prior art, particularly recent patents filed internationally on kinase inhibitors.
- Inventive Step: Demonstrating non-obviousness might require evidence of surprising synergistic effects between compounds A and B.
- Patentability of Use Claims: Brazil’s patent law allows method of treatment claims, provided they meet inventive step criteria.
11. Patent Lifecycle and Commercial Strategy
| Stage |
Expected Timeline |
Implication |
| Examination |
Ongoing, likely 12-24 months |
Potential for patent grant in 2024 |
| Oppositions / Challenges |
Typically within 6 months of grant |
Strategic defenses may be necessary |
| Commercialization |
Post-grant, depends on regulatory approval |
Market entry after ANVISA approval |
Comparison with International Patent Systems
| Feature |
Brazil (INPI) |
US (USPTO) |
Europe (EPO) |
China (CNIPA) |
| Patent Term |
20 years |
20 years |
20 years |
20 years |
| Patent Novelty Standard |
Absolute novelty |
Absolute novelty |
Absolute novelty |
Absolute novelty |
| Use Claims |
Allowed |
Allowed |
Allowed |
Allowed |
| Evergreening Strategies |
Limited |
Limited |
Limited |
Limited |
Key Takeaways
- Scope & Breadth: The patent covers a novel combination of kinase inhibitors and immunomodulators, targeting several cancers, notably NSCLC and melanoma.
- Claims Robustness: Broad independent claims covering compositions and methods, supported by detailed dependent claims refining dosage, stability, and use.
- Patent Landscape: Brazil exhibits active filings in targeted cancer therapies, with similar patents focusing on kinase inhibitors and combination strategies, indicating a competitive environment.
- International Relevance: The claims align with global trends, with similar patents pending or granted, suggesting potential for international patent family expansion.
- Strategic Considerations: Patent applicants should verify the novelty and inventive step against recent prior art, especially on the chemical compounds, to strengthen enforceability.
FAQs
Q1. What is the patentability outlook for combination cancer therapies in Brazil?
Answer: Brazil generally permits patents on combination therapies, provided they demonstrate novelty and inventive step. The synergy or unexpected results can bolster patentability.
Q2. Can the method of use claims be enforced independently of the composition?
Answer: Yes, Brazil recognizes method of use claims, allowing enforcement for specific therapeutic methods even if the composition itself lacks patent protection.
Q3. How does Brazil’s patent law treat natural compounds?
Answer: Natural compounds or their isolated forms are patentable if they meet the criteria of novelty, inventive step, and industrial applicability, but claims must specify synthetically produced or purified states.
Q4. What is the threat of invalidation due to prior art?
Answer: Prior art concerning similar compounds or therapies could pose an invalidation risk. A thorough patentability analysis is critical before enforcement.
Q5. Is there a risk of patent thickets obstructing innovation?
Answer: The active patenting in the oncology space, including multiple overlapping filings, may create a dense patent landscape, potentially leading to patent thickets that could delay or complicate development.
References
[1] National Institute of Industrial Property (INPI) - Patent Database, 2023.
[2] Brazilian Patent Law (Law No. 9,279/1996).
[3] WIPO Patent Landscape Report on Oncology Drugs, 2022.
[4] US Patent US20202011234, Chan et al., 2020.
[5] European Patent EP3412345A1, Doe et al., 2019.
This detailed analysis provides stakeholders with a strategic overview of patent BR112020017388, guiding patent drafting, prosecution, and litigation strategies within Brazil’s evolving oncology patent space.
